Search Within

Sophia Chiu

Formats
  1. Journal Article (3)
  2. Meeting Abstract (3)
Groups
  1. Adult Leukemia (6)
  2. Center for Hematologic Malignancies (6)
  3. Center for Molecular Imaging and Biotechnology (CMIB) (6)
  4. Department of Medicine (6)
  5. Executive Committee, Center for Hematologic Malignancies (6)
  6. GSK Faculty (6)

More Groups

People
  1. Ross Levine (6)
  2. Maria Kleppe (4)
  3. Matthew Keller (4)
  4. Brittany Woods (2)
  5. Franck Rapaport (2)
  6. Lilly Gu (2)

More People

Years
  1. 2019 (2)
  2. 2018 (1)
  3. 2017 (1)
  4. 2016 (1)
  5. 2015 (1)
Publications
  1. Blood (2)
  2. Cancer Cell (1)
  3. Clinical Cancer Research (1)
  4. Journal of Clinical Investigation (1)
  5. Swiss Medical Weekly (1)
Publishers
  1. American Society of Hematology (2)
  2. American Association for Cancer Research (1)
  3. American Society for Clinical Investigation (1)
  4. Cell Press (1)
  5. E M H Swiss Medical Publishers Ltd (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Activation of JAK/STAT signaling in megakaryocytes sustains myeloproliferation in vivo
    Journal Article

    Woods, B.; Chen, W.; Chiu, S.; Marinaccio, C.; Fu, C.; Gu, L.; Bulic, M.; Yang, Q.; Zouak, A.; Jia, S.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms
    Journal Article

    Stivala, S.; Codilupi, T.; Brkic, S.; Baerenwaldt, A.; Ghosh, N.; Hao-Shen, H.; Dirnhofer, S.; Dettmer, M. S.; Simillion, C.; Kaufmann, B. A.; more...
    Journal of Clinical Investigation (2019)

    Fulltext@MSK | Save
  • ERK and MEK kinases as novel therapeutic targets in myeloproliferative neoplasms based on bypass MAPK pathway activation
    Meeting Abstract

    Stivala, S.; Baerenwaldt, A.; Codilupi, T.; Ghosh, N.; Hao-Shen, H.; Dirnhofer, S.; Dettmer, M. S.; Simillion, C.; Chiu, S.; Keller, M.; more...
    Swiss Medical Weekly (2018)

    Fulltext@MSK | Save
  • Targeting cell non-autonomous MAPK activation as a novel therapeutic strategy in myeloproliferative neoplasms
    Meeting Abstract

    Meyer, S. C.; Ghosh, N.; Stivala, S.; Baerenwaldt, A.; Hao-Shen, H.; Dirnhofer, S.; Dettmer, M. S.; Simillion, C.; Chiu, S.; Keller, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Activation of JAK/STAT signaling in megakaryocytes is necessary and sufficient for myeloproliferation in vivo
    Meeting Abstract

    Wen, Q. J.; Woods, B.; Yang, Q.; Sophia, C.; Lillu, G.; Rapaport, F.; Levine, R. L.; Crispino, J.
    Blood (2016)

    Fulltext@MSK | Save
  • CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms
    Journal Article

    Meyer, S.; Keller, M.; Chiu, S.; Koppikar, P.; Guryanova, O.; Rapaport, F.; Xu, K.; Manova, K.; Pankov, D.; O'reilly, R.; more...
    Cancer Cell (2015)

    Fulltext@MSK | Save